Identity and synonyms
Not mecasermin and not IGF-DES.
Synonyms: Long R3 IGF-I · IGF-1LR3 · LR8 (STELLA parenthesis; unresolved, not accepted synonym)
Protein or biologic · Protein or protein analogue
Detailed molecular class: IGF analogue protein
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
IGF-1 receptor signaling with altered binding-protein affinity.
Evidence and critical reading
Reported scientific and empirical uses
Reported muscle and performance
Protein analogue offered for anabolism; neither mecasermin nor IGF-DES.
Human evidence
No controlled human efficacy finding was verified for the exact catalog identity in this screen.
Preclinical evidence
Fetal sheep study did not show the claimed growth benefit; experimental context differs from adult bodybuilding.
Critical reading and limitations
A growth-restricted fetal-sheep study did not improve growth; not athlete validation.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
20–40 mcg · Total daily amount
- Frequency
- Daily, described as initial
- Duration
- 4–6 weeks per handbook
- Route
- SC or IM per source
- Context
- Hypertrophy claim; not equivalent to authorized mecasermin.
- Presentation
- Not stated on selected page.
- Interpretation
- Regimen attributed to handbook, without clinical validation for this use; not a recommendation.
manual07 · Page 36 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
80–120 mcg · Total daily amount
- Frequency
- Daily, described as advanced
- Duration
- 4–6 weeks per handbook
- Route
- SC or IM per source
- Context
- Handbook experience label, without validation as safe escalation.
- Presentation
- Not stated on selected page.
- Interpretation
- Regimen attributed to handbook, without clinical validation for this use; not a recommendation.
manual07 · Page 36 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Human safety, contraindications and interactions are not adequately established for the catalog product. Missing reports are not evidence of safety.
Changes metabolic signaling; hypoglycemia/other risks need product-specific assessment without importing other molecules’ labels.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
IGF-1 LR3 · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID33587816
Mongongu C, Coudoré F, Domergue V, Ericsson M, Buisson C, Marchand A.
October 16, 2026
- PMID39679943
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
White A, Stremming J, Wesolowski SR, Al-Juboori SI, Dobrinskikh E, Limesand SW, Brown LD, Rozance PJ.
October 16, 2026
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026